AbbVie vs Kia: Revenue, Profit and Business Model
AbbVie reported $61.2B of revenue in FY2025 and $4.2B of net income. Kia reported ~$81B of revenue in FY2025 and ~$5.4B of net income.
Latest financial snapshot
Financial summary
AbbVie
AbbVie reported $61.160 billion of FY2025 net revenue and $4.226 billion of net income. Skyrizi and Rinvoq generated $25.866 billion combined, while Humira declined to $4.540 billion after U.S. biosimilar entry. The 2020 Allergan acquisition added neuroscience and aesthetics revenue, and the 2024 ImmunoGen and Cerevel acquisitions added oncology and neuroscience assets.
Kia
Kia's revenue has risen every year since 2020: from ~$49.6 billion (KRW 69.9 trillion) in 2021 to ~$76.3 billion (KRW 107.4 trillion) in 2024 and a record ~$81 billion (KRW 114.1 trillion) in 2025 (+6.2%). Profit has not kept up. Operating profit fell 28.3% in 2025 to ~$6.45 billion (KRW 9.08 trillion), and the margin dropped from 11.8% to 8.0% as US tariffs and incentives ate into earnings. Net profit was about $5.36 billion (KRW 7.55 trillion). The squeeze continued into 2026. Q1 revenue was a record ~$20.9 billion (KRW 29.50 trillion) (+5.3%), but operating profit fell 26.7% to ~$1.57 billion (KRW 2.21 trillion). Q2 revenue reached ~$23.5 billion (KRW 33.04 trillion) (+12.6%) while operating profit fell 4.9% to ~$1.87 billion (KRW 2.63 trillion). The shares dropped about 13% on the day of the Q2 results. Shareholder returns are still high: the 2025 dividend was KRW 6,800 per share, a 35% consolidated payout ratio, and Kia has been cancelling treasury shares, cutting issued shares from 405.4 million in 2022 to 390.4 million at the end of 2025.
Revenue and profit by year
AbbVie
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $61.2B | $4.2B | 6.9% | +8.6% | Source |
| FY2024 | $56.3B | $4.3B | 7.6% | +3.7% | Source |
| FY2023 | $54.3B | $4.9B | 9.0% | -6.4% | Source |
| FY2022 | $58.1B | $11.8B | 20.4% | +3.3% | Source |
| FY2021 | $56.2B | $11.5B | 20.5% | +22.7% | Source |
| FY2020 | $45.8B | $4.6B | 10.1% | +37.7% | Source |
| FY2019 | $33.3B | $7.9B | 23.7% | +1.6% | Source |
| FY2018 | $32.8B | $5.7B | 17.4% | +16.1% | Source |
| FY2017 | $28.2B | $5.3B | 18.8% | +10.1% | Source |
| FY2016 | $25.6B | $6B | 23.2% | — | Source |
Where the revenue comes from
AbbVie
- Immunology Portfolio49.7%
FY2025 revenue was $30.406 billion, led by Skyrizi, Rinvoq, and Humira.
- Neuroscience Portfolio17.6%
FY2025 revenue was $10.767 billion, including Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta.
- Oncology Portfolio10.9%
FY2025 revenue was $6.655 billion, including Imbruvica, Venclexta, and Elahere.
- Aesthetics Portfolio7.9%
FY2025 revenue was $4.860 billion, including Botox Cosmetic and Juvederm.
- Other Products and Revenue13.9%
The remaining FY2025 revenue came from eye care, other specialty products, and other revenue.
Kia
- Global Vehicle Sales
primary revenue source
Kia generates most revenue from selling SUVs, passenger cars, hybrids, EVs, and commercial vehicles through regional subsidiaries, importers, dealers, and fleet channels.
- Parts, Service, and Accessories
recurring support revenue
Genuine parts, aftersales service, accessories, and warranty-related activity provide higher-repeat revenue tied to Kia's installed vehicle base.
- Future Mobility and PBVs
emerging growth area
Dedicated EVs, software-defined vehicles, purpose-built vehicles, and connected services support Kia's longer-term mobility strategy.
Business model and strategy
AbbVie
How it makes money
AbbVie earns revenue from global sales of prescription medicines and Allergan Aesthetics products. Its FY2025 portfolios were led by immunology at $30.406 billion, neuroscience at $10.767 billion, oncology at $6.655 billion, and aesthetics at $4.860 billion. The company funds internal research and supplements its pipeline through licensing and acquisitions.
Growth strategy
AbbVie is expanding approved uses and commercial reach for Skyrizi and Rinvoq while investing in oncology and neuroscience. ImmunoGen added Elahere and antibody-drug conjugate programs, Cerevel added clinical-stage neuroscience programs, and Allergan added Botox, Vraylar, migraine products, eye care, and aesthetics.
Competitive advantage
AbbVie's scale rests on its immunology portfolio, specialist commercial infrastructure, approved products across several therapeutic areas, and acquired oncology, neuroscience, and aesthetics assets. Those strengths are offset by patent-expiration, clinical-development, safety, reimbursement, and pricing risks described in its Form 10-K.
Kia
How it makes money
Kia makes money mainly by building and selling vehicles wholesale to its regional sales subsidiaries, importers and franchised dealers, which then sell to retail and fleet buyers. SUVs and RVs such as the Sportage, Sorento, Seltos, Carnival and Telluride make up most of the mix and earn more per unit than small sedans.
Growth strategy
Kia's current strategy, set out at the 2026 CEO Investor Day, uses several powertrains instead of only EVs. It plans to grow EVs (EV3, EV4, EV5, EV6, EV9 and later models) and hybrids together, add a PBV line of modular electric vans starting with the PV5, and build up software-defined vehicles, autonomous driving and robotics as longer-term businesses.
Competitive advantage
Kia's main advantages are its scale inside Hyundai Motor Group and the way it can switch powertrains easily. Sharing platforms, the E-GMP 800V EV architecture, batteries, chips and logistics (Hyundai Glovis) with Hyundai lowers development and purchasing costs. Factories in Korea, the US (Georgia), Mexico, Slovakia and India let Kia shift production between combustion, hybrid and electric models.
Questions about AbbVie vs Kia
Which company has higher revenue — AbbVie Inc. or Kia Corporation?
AbbVie Inc. reported $61.2B (FY2025), while Kia Corporation reported ~$81B (FY2025). By last reported revenue, Kia Corporation is the larger business, with AbbVie Inc. reporting a smaller revenue base.
What is the market cap of AbbVie Inc. vs Kia Corporation?
AbbVie Inc.'s market capitalisation stands at $465.8B, while Kia Corporation's is $32.4B. AbbVie Inc. carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Kia Corporation.
Which is more financially efficient — AbbVie Inc. or Kia Corporation?
AbbVie Inc. generates $1.07M / employee in revenue per employee, while Kia Corporation generates $1.52M / employee. Kia Corporation shows higher revenue efficiency per headcount, though this reflects business model differences — capital-light software companies routinely outperform labour-intensive manufacturers on this metric.
How do AbbVie Inc. and Kia Corporation make money?
AbbVie Inc. and Kia Corporation generate revenue in fundamentally different ways. AbbVie Inc.: AbbVie earns revenue from global sales of prescription medicines and Allergan Aesthetics products. Kia Corporation: Kia makes money mainly by building and selling vehicles wholesale to its regional sales subsidiaries, importers and franchised dealers, which then sell to retail and fleet buyers.
Which company is valued higher relative to revenue — AbbVie Inc. or Kia Corporation?
On a price-to-sales (P/S) basis, AbbVie Inc. trades at 7.6x P/S and Kia Corporation at 0.4x P/S. AbbVie Inc. commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Kia Corporation. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.
Is AbbVie Inc. bigger than Kia Corporation?
By last reported revenue, Kia Corporation (~$81B (FY2025)) is the larger company compared to AbbVie Inc. ($61.2B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AbbVie vs Kia overview